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sponders. Decreasing the size of the classifier set to 4 genes 
( PDGFB ,  PCGF3 ,  CISH , and  ANXA5 ) increased the accuracy to 
100%. Expression levels by real-time PCR for validation were 
well correlated with those 4 genes in microarrays.  Conclu-
sion: The genes identified may serve as efficient biomarkers 
for personalized cancer-targeted therapy. 
 © 2017 S. Karger AG, Basel 
 Introduction 
 Gastric cancer is the leading cause of cancer-related 
death worldwide and is a major health problem in South-
east Asian countries including Japan  [1, 2] . Although 
mortality from gastric cancer has been declining recently 
due to improvements in early diagnosis and treatment, 
the prognosis of patients with advanced gastric cancer 
(AGC) remains poor.
 The efficacy of various combinations of fluoropyrimi-
dine, irinotecan, platinum drugs, and anthracyclines has 
been investigated for the treatment of metastatic gastric 
cancers. Webb et al.  [3] performed a prospective random-
ized study that compared the efficacy of a combination of 
epirubicin, cisplatin, and protracted venous infusion with 
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 Abstract 
 Objectives: The aim of this study was to identify biomarkers 
for predicting the efficacy of docetaxel, cisplatin, and S-1 
(DCS) therapy for advanced gastric cancer using microarrays 
of biopsy specimens before chemotherapy.  Methods: Nine-
teen samples were taken from 19 patients with unresectable 
metastatic gastric cancer who received DCS as a first-line 
therapy. Laser capture microdissection was performed, and 
total cellular RNA was extracted from each microdissected 
sample. Whole-gene expression was analyzed by microar-
ray, and the difference in mRNA expression observed with 
the microarrays was confirmed by quantitative real-time 
PCR. Immunohistochemical staining was performed using 
clinical tissue sections obtained by endoscopic biopsy.  Re-
sults: Eleven patients were identified as early responders 
and 8 patients as nonresponders to DCS therapy. Twenty-
nine genes showed significant differences in relative expres-
sion ratios between tumor and normal tissues. A classifier set 
of 29 genes had high accuracy (94.7%) for distinguishing 
gene expression between 11 early responders and 8 nonre-
 Received: December 6, 2016 
 Accepted after revision: February 17, 2017 
 Published online: May 17, 2017 
 Prof. Tetsuji Takayama 
 Department of Gastroenterology and Oncology 
 Institute of Biomedical Sciences, Tokushima University Graduate School 
 Tokushima 770-8503 (Japan) 
 E-Mail takayama   @   tokushima-u.ac.jp 
 © 2017 S. Karger AG, Basel 
 www.karger.com/ocl 
 Kitamura   et al.Oncology
DOI: 10.1159/000464329
2
fluorouracil (5-FU) (ECF) with the standard combina-
tion of 5-FU, doxorubicin, and methotrexate (FAMTX) 
in previously untreated patients with advanced esopha-
gogastric cancer. The ECF regimen resulted in a survival 
and response advantage, tolerable toxicity, and better 
quality of life and cost-effectiveness compared with
FAMTX chemotherapy. Van Cutsem et al.  [4] conducted 
a phase III study of docetaxel and cisplatin plus 5-FU 
compared with cisplatin and 5-FU as a first-line therapy 
for AGC. Addition of docetaxel to cisplatin and 5-FU sig-
nificantly improved the time to progression, survival, and 
response rate in gastric cancer patients but resulted in 
some increases in toxicity. Recently, Kilickap et al.  [5] 
suggested that combination therapy with docetaxel/
cisplatin/5-FU is superior in terms of overall response 
rate and progression-free survival as compared to 
cisplatin/5-FU and ECF combinations in AGC.
 We have reported that a triple-drug combination che-
motherapy regimen consisting of docetaxel, cisplatin, 
and S-1 (DCS) is well tolerated in patients with metastat-
ic gastric cancer and has a very high response rate (87.1%), 
a high downstaging rate (25.8%), and a high curative sur-
gery rate (22.6%)  [6, 7] . A subsequent phase II study of 
this regimen also showed a high response rate (81%)  [8] . 
In a phase II study of neoadjuvant chemotherapy, preop-
erative treatment with DCS for localized AGC demon-
strated a sufficient R0 resection rate and a good patho-
logical response with manageable toxicities  [9] , and a 
phase III trial is currently in progress. Although DCS 
therapy shows very high efficacy for metastatic gastric 
cancer, there still are unresponsive cases, and grade 3–4 
neutropenia and leukocytopenia are often observed. 
Therefore, it is very important to discover biomarkers to 
aid in the selection of appropriate candidates for this ther-
apy. In this study, we conducted a clinicopathological 
analysis to identify biomarkers for predicting the efficacy 
of DCS using microarray analysis of biopsy samples be-
fore chemotherapy.
 Materials and Methods 
 Patients, Samples, and Study Design 
 Patients with unresectable metastatic gastric cancer (clinical 
stage III or IV) who received DCS as a first-line therapy were ret-
rospectively screened. The patients were classified into 3 groups 
based on tumor regression rates (TRR) according to the Response 
Evaluation Criteria in Solid Tumors (RECIST)  [10] after 2 cycles 
of treatment: an early responder group showing >20% TRR, a re-
sponder group showing 10–20% TRR, and a nonresponder group 
showing <10% TRR  [11, 12] . There were no patients who showed 
>20% TRR after 3 cycles or more. Prior to chemotherapy, all pa-
tients underwent biopsy from tumor and background gastric mu-
cosa under endoscopic examination. Tumor samples for histolog-
ic examination were fixed in 10% buffered formaldehyde, and tu-
mor samples for gene expression analysis were frozen in liquid 
nitrogen and stored at –80  °  C until use.
 Treatment with DCS Combination Therapy 
 S-1 was administered orally twice daily on days 1–14 at a dose
of 60 mg/m 2 . Docetaxel 50 mg/m 2 was given by intravenous infu-
sion for 1.5 h. Subsequently, cisplatin was administered by intra-
venous infusion for 2 h at 60 mg/m 2 in saline solution on day 8. 
Cycles were repeated every 3 weeks. To avoid cisplatin-induced 
renal damage, patients were hydrated on days 7–9 with 2,000 mL 
of 5% dextrose in 0.9% sodium chloride. Prophylactic administra-
tion of antiemetic medication (5-HT 3 antagonist, corticosteroid, 
and aprepitant) at a standard dose was routinely used to prevent 
nausea and vomiting when cisplatin was administered. Granulo-
cyte colony-stimulating factor was administered when grade 4 
neutropenia or grade 3 or 4 neutropenia with high-grade fever 
were observed.
 Microdissection 
 Laser capture microdissection was performed on 19 frozen tis-
sue samples including gastric cancer lesions and normal tissue in 
the background mucosa. We stained thick frozen sections with he-
matoxylin and eosin and selectively collected cancer cells and nor-
mal cells under an inverted microscope (CKX41, Olympus, Tokyo, 
Japan) incorporated in a laser microdissection system (MMI Cell-
Cut, Molecular Machines and Industries Germany), which was de-
signed for quick and precise isolation of cells and tissue.
 RNA Extraction and Microarray Analysis 
 Total cellular RNA was extracted from each microdissected 
sample. The quality of the purified RNA was assessed with an Ag-
ilent 2100 Bioanalyzer using an RNA 6000 Nano LabChip Kit (Ag-
ilent Technologies, Palo Alto, CA, USA). Total RNA (50 ng) was 
amplified with WT-Ovation FFPE RNA Amplification System V2 
(NuGEN, San Carlos, CA, USA) and biotin labeled with FL-Ova-
tion cDNA Biotin Module V2 (NuGEN). Prepared cDNA was add-
ed to a whole human genome oligo DNA microarray (4 × 44 k; 
Agilent). Hybridization was performed at 65   °   C for 17 h. After 
washing, fluorescence intensity was assayed using a scanner 
(G2565BA; Agilent). The signal intensities of Cy3 were quantified 
and analyzed by subtracting background using Feature Extraction 
(Agilent). GeneSpring GX10.0.2 analysis software (Agilent) was 
used to normalize data and to identify 13,174 genes with fluores-
cence intensities >100 in at least 1 RNA sample. The complete da-
tasets were deposited in the Gene Expression Omnibus database 
(accession No. GSE31811).
 Microarray Data Analysis 
 Microarray data were analyzed using the GX10.0.2 software. In 
all experimental groups, differentially expressed genes were identi-
fied by a significance level of  p < 0.01 and a threshold level of a >3-
fold change. The prediction scores of all samples were obtained by 
a leave-one-out approach, in which one sample at a time was re-
moved from the sample set  [13] . We also used  N -fold cross-vali-
dation  [14] . The classes in the input data are randomly divided into 
 N equal parts;  N – 1 parts are used for training, and the remaining 
1 part is used for testing.
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 Quantitative Real-Time PCR of mRNA 
 The difference in mRNA expression observed with the micro-
arrays was confirmed by quantitative real-time (qRT)-PCR analy-
sis of individual samples. Equal amounts of DNA-free RNA from 
each sample were used. qRT-PCR was performed using an ABI 
7500 system with specific primer and probe sets for the TaqMan 
probe detection assay (Applied Biosystems, Foster City, CA, USA) 
according to the manufacturer’s instructions. β-Actin was used as 
an endogenous quantity control.
 Immunohistochemical Analysis 
 To confirm the differential expression of marker genes between 
early responders and nonresponders, clinical tissue sections ob-
tained by endoscopic biopsy were stained using LSAB TM 2 Kit/HRP 
(DAKO, Tokyo, Japan). Briefly, after endogenous peroxidase and 
protein blocking reactions, the primary antibodies of PDGFB 
(ab23914, Abcam, Cambridge, UK), PCGF3 (HPA018487, Sigma-
Aldrich, St. Louis, MO, USA), cytokine-inducible SH2-containing 
protein (CISH; sc-74581, Santa Cruz Biotechnology Inc., Dallas, 
TX, USA), or annexin A5 (ANXA5; H00000308-MO1, Abnoba, 
Taiwan) were added, followed by HRP-labeled anti-rabbit or anti-
mouse IgG as the secondary antibody. The specimens were coun-
terstained with hematoxylin. Positivity of immunostaining was as-
sessed as absent or present by 2 independent investigators without 
prior knowledge of the clinical follow-up data. Cases were accept-
ed as positive only when reviewers independently defined them as 
such.
 Statement of Ethics 
 This study was approved by the Institutional Review Board of 
Tokushima University Hospital. Written informed consent was 
obtained from each patient before they underwent tumor biopsy.
 Results 
 Characteristics of the Patients 
 A total of 19 patients were enrolled in this study. Ac-
cording to RECIST criteria  [10] , 11 patients were identi-
fied as early responders and 8 patients as nonresponders 
by 3 board-certified gastroenterologists. There were no 
patients in the responder group showing 10–20% TRR. 
Characteristics of the 11 early responders and 8 nonre-
sponders are shown in  Table 1 . The mean age of the 19 
cases (11 male, 8 female) was 59.9 years (range 33–76). 
There was no statistical difference between the 2 groups. 
Histopathological types were poorly differentiated ade-
nocarcinoma in 17 cases and differentiated adenocarci-
noma in 2 cases.
 Identification of Genes Associated with Sensitivity to 
DCS Treatment 
 To extract differentially expressed genes of 11 early re-
sponders and 8 nonresponders, we compared the expres-
sion levels of 13,174 genes after quality checking. The rel-
ative expression ratios between tumor and normal tissues 
in each patient were calculated. We found 29 genes that 
showed significant differences in relative expression ra-
tios between tumor and normal tissues (unpaired  t test,
 p < 0.01), and these genes showed 3-fold or greater chang-
es. The 29 genes are listed in  Table 2 .
 Prediction of the Efficacy of DCS Treatment 
 On the basis of the expression profiles of the 29 genes, 
we analyzed their potential for predicting the efficacy of 
DCS treatment. Hierarchical clustering of the 29 genes 
comparing the early responder group and the nonre-
sponder group is shown in a heat map ( Fig. 1 ). The green 
or red colors of each block represent the normalized 
gene expression levels. Prediction scores were calculated 
according to the procedures described in the Materials 
and Methods section. A classifier set of 29 genes showed 
high accuracy (94.7%) for distinguishing gene expres-
sion between the 11 early responders and the 8 nonre-
sponders, as evaluated by the leave-one-out algorithm. 
With the  N -fold approach, a similarly high classification 
accuracy (94.7%) was obtained with the 29 gene sets 
( Fig. 2 ;  Table 3 ). Decreasing the size of the classifier set 
to 4 genes ( PDGFB ,  PCGF3 ,  CISH , and  ANXA5 ) in-
creased the accuracy to 100% with both the leave-one-
out and  N -fold methods ( Table  4 ).  PDGFB ,  PCGF3 , 
 CISH , and  ANXA5 genes were differentially expressed 
in early responders and nonresponders and had a good 
predictive accuracy for the classification of treatment 
outcome.
 Table 1.  Patient characteristics
Early
Responder
Non-
responder
Total patients 11 8
Median age (range), years 59.5 (34 – 76) 60.6 (33 – 75)
Sex
Male 4 7
Female 7 1
Performance status
0 7 5
1 4 3
Differentiation
Intestinal 2 0
Diffuse 9 8
Clinical stage
III 0 2
IV 11 6
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 Validation of mRNA Levels of PDGFB, PCGF3, CISH, 
and ANXA5 
 To validate the expression levels of PDGFB, PCGF3, 
CISH, and ANXA5 mRNA in the early responder and 
nonresponder groups, we performed TaqMan qRT-PCR 
and compared expression levels with signal intensity by 
microarray ( Fig.  3 ). We obtained expression ratios be-
tween tumor and normal tissues. In the analysis of all 19 
subjects, we found high, moderate, and weak correlations 
with CISH ( r 2 = 0.567), PDGFB ( r 2 = 0.338), and PCGF3 
( r 2 = 0.248) but not with ANXA5 ( r 2 = 0.162). The data 
obtained by TaqMan qRT-PCR were well correlated with 
those from microarray analysis.
 Immunohistochemical Validation of PDGFB, PCGF3, 
CISH, and ANXA5 
 To validate the differential expression of predictive 
protein markers in the early responder and nonresponder 
groups, we carried out immunohistochemical staining 
with antibodies for PDGFB, PCGF3, CISH, and ANXA5 
( Fig.  4 ). In the case of nonresponders, expression of 
PDGFB was low, but CISH, ANXA5, and PCGF3 were 
highly expressed. In contrast, expression of PDGFB was 
increased, but resistant markers of CISH, ANXA5, and 
PCGF3 were decreased in early responders. These immu-
nohistochemical results were consistent with the micro-
array data.
 Table 2. List of 29 candidate genes for discriminating early responders from nonresponders to DCS therapy
ID Symbol Gene name p value Regulation
1 PCGF3 Homo sapiens polycomb group ring finger 3 (PCGF3) <0.01 down
2 STYX Serine/threonine/tyrosine-interacting <0.01 down
3 Q9H7N0 HUMAN FAM39B protein <0.01 up
4 B4GALT5 Homo sapiens UDP-Gal:betaGlcNAc beta 1,4-galactosyltransferase, polypeptide 5 <0.01 down
5 EGR1 Homo sapiens early growth response 1 <0.01 down
6 BC062753 Homo sapiens cDNA clone IMAGE: 3933366, partial cds <0.01 up
7 PSMD11 Homo sapiens proteasome (prosome, macropain) 26S subunit, non-ATPase, 11 <0.01 up
8 PDGFB Homo sapiens platelet-derived growth factor beta polypeptide <0.01 up
9 HECA Homo sapiens headcase homolog <0.01 down
10 DB365607 DB365607 NT2RP2 Homo sapiens cDNA clone NT2RP2003447 3′, mRNA sequence <0.01 down
11 ANTXR2 Homo sapiens anthrax toxin receptor 2 <0.01 down
12 ATP7B Homo sapiens ATPase, Cu++ transporting, beta polypeptide <0.01 down
13 ANXA5 Homo sapiens annexin A5 <0.01 down
14 ENST00000373575 Eukaryotic translation initiation factor 4E type 2 <0.01 up
15 CISH Homo sapiens cytokine inducible SH2-containing protein <0.01 down
16 PLK2 Homo sapiens polo-like kinase 2 <0.01 down
17 E01979 xq40c08.x1 NCI_CGAP_Lu28 Homo sapiens cDNA clone IMAGE:2753102 3′ similar 
to gb:X57352 INTERFERON-INDUCIBLE PROTEIN 1-8U (HUMAN);, mRNA 
sequence [AW275876]
<0.01 down
18 TRBV5-4 Homo sapiens T cell receptor beta variable 5-4, mRNA <0.01 up
19 ENST00000307437 PREDICTED: Homo sapiens similar to ribosomal protein S12 <0.01 down
20 ERLIN1 Homo sapiens ER lipid raft associated 1 <0.01 down
21 LOC441073 PREDICTED: Homo sapiens similar to 60S ribosomal protein L26 <0.01 down
22 JMJD2A Homo sapiens jumonji domain containing 2A <0.01 up
23 HP1BP3 Homo sapiens heterochromatin protein 1, binding protein 3 <0.01 up
24 THC2535233 Q4T2V2_TETNG (Q4T2V2) Chromosome 10 SCAF10171, whole genome shotgun 
sequence
<0.01 down
25 AVPI1 Homo sapiens arginine vasopressin-induced 1 <0.01 down
26 DB329052 DB329052 PLACE7 Homo sapiens cDNA clone PLACE7013977 3′, mRNA sequence <0.01 down
27 MYCBP2 Homo sapiens MYC binding protein 2 <0.01 up
28 FAM116A Homo sapiens family with sequence similarity 116, member A <0.01 down
29 AP1S1 Homo sapiens adaptor-related protein complex 1, sigma 1 subunit <0.01 down
DCS, docetaxel, cisplatin, and S-1.
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 Fig. 1. Hierarchical clustering of the 29 genes comparing the early responder and nonresponder groups is shown 
in a heat map. High expression is shown in red and low expression in green. Early responders and nonresponders 
are well distinguished. R, responders; NR, nonresponders. 
 Fig. 2. Prediction accuracy by gene number. The prediction accu-
racy was 100% with only 4 genes. 
 Table 3. Validation in 29 genes
 Prediction
effectiv e noneffective accuracy
Leave-one-out validation
True effective 11 0 100%
True noneffective 1 7 87.50%
Total (18/19) 94.70%
N-fold validation
True effective 11 0 100%
True noneffective 1 7 87.50%
Total (18/19) 94.70%
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 Discussion 
 Recent studies using microarray analysis have demon-
strated a relationship between gastric cancer progression, 
metastasis, and genetic expression; however, there are few 
reports regarding sensitivity or resistance to anticancer 
drugs  [15, 16] . In this study, we conducted a clinicopath-
ological investigation to identify biomarkers for predict-
ing the efficacy of DCS therapy, which is the most effec-
tive regimen for AGC, using biopsy samples taken before 
chemotherapy and microarray analysis. We determined 
the whole genome sequence and investigated the ge-
nome-affecting sensitivity and resistance to DCS therapy.
 Gastric cancer tissues are composed of complex ad-
mixtures of different cell types including inflammatory 
and necrotic cells, and the procurement of pure samples 
is indispensable for identifying causative genes. Thus, la-
ser capture microdissection was performed, and total cel-
lular RNA was extracted from microdissected samples. 
As a result, 29 genes affecting the therapeutic efficacy of 
DCS were identified. The classifier set of 29 genes showed 
high accuracy (94.7%) for distinguishing between the 11 
early responders and the 8 nonresponders using both the 
leave-one-out and  N -fold algorithms. Decreasing the size 
of the classifier set to 4 genes ( PDGFB ,  PCGF3 ,  CISH , and 
 ANXA5 ) increased the accuracy to 100% with both meth-
ods. Expression patterns of these 4 genes in the early re-
sponder and nonresponder groups were correlated with 
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 Fig. 3. Comparison of quantitative real-time PCR and microarray expression of PDGFB, PCGF3, CISH, and 
ANXA5. Expression ratios between tumor and normal tissues are shown. The results are indicated as white (Taq-
Man) and blue bars (microarray). R, responders; NR, nonresponders. 
 Table 4. Validation in 4 genes
Prediction
effective noneffective accuracy
Leave-one-out validation
True effective 11 0 100%
True noneffective 0 8 100%
Total (19/19) 100%
N-fold validation
True effective 11 0 100%
True noneffective 0 8 100%
Total (19/19) 100%
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the treatment outcome. The results demonstrate a poten-
tially predictive value in DCS therapy.
 PDGFB is a member of the platelet-derived growth 
factor family and is known as an important factor in neo-
plasms, such as lung, breast, and colorectal cancers  [17] . 
PDGF contributes to cancer development and progres-
sion by both autocrine and paracrine signaling mecha-
nisms. It is also well known that cancer development is 
often associated with neovascularization  [18] , and PDGF 
also plays a role in vascular development. Our results 
showed that PDGF was a sensitive marker of DCS effi-
cacy, and these characteristics are presumably the reason 
why PDGF is predictive of DCS efficacy.
 CISH protein is encoded by the  CISH gene and is a 
known suppressor of cytokine signaling (SOCS), i.e., a 
STAT-induced STAT inhibitor  [19] . With respect to can-
cer, CISH protein has been hypothesized to act as an ac-
tivator of the MAPK pathway and as an inhibitor of dif-
ferentiated cell functions mediated through the JAK/
STAT pathway. The role of CISH protein in tumor pro-
gression (i.e., positive effects on cell proliferation and col-
ony formation) has been demonstrated  [20] .
 PCGF3, the protein encoded by this gene, contains a 
C3HC4-type RING finger, which is a motif known to be 
involved in protein-protein interactions. The specific 
function of this protein has not yet been determined and 
is poorly described in the field of oncology. It has re-
cently been reported that RING1 protein expression 
may be a favorable independent prognostic parameter 
for non-small cell lung cancer  [21] , but it is unclear how 
this molecule may be involved in tumor proliferation 
and resistance to anticancer drugs in patients with gas-
tric cancer.
 Annexins are important in various cellular and physi-
ological processes and have been shown to be involved in 
trafficking and organization of vesicles, exocytosis, endo-
 Fig. 4. Immunohistochemical staining for PDGFB, PCGF3, CISH, and ANXA5 in a specimen from an early re-
sponder case. Expression of PDGFB was high, but expression of CISH, ANXA5, and PCGF3 was low. 
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cytosis, and calcium ion channel formation  [22] . One 
type of annexin, ANXA2, is involved in gastric cancer 
multidrug resistance via regulation of the p38MAPK and 
AKT pathways, as well as in multidrug resistance  [23] . 
ANXA5 is a potentially predictive marker in tumors, and 
it promotes a variety of cancers. It is involved in metasta-
sis, invasion, angiogenesis, and cancer progression. 
ANXA5 deregulation is associated with drug resistance in 
nasopharyngeal carcinoma and gastric cancer, and the 
cell sensitivity to cisplatin, paclitaxel, and 5-FU is in-
creased by 36-, 17-, and 4-fold, respectively, following the 
downregulation of ANXA5  [24] .
 We focused on the aforementioned combination of 4 
proteins and conducted immunohistochemical staining 
for the samples after DCS therapy. We had effective cas-
es showing positive PDGFB and negative CISH, PCGF3, 
and ANXA5 responses ( Fig.  4 ) as well as noneffective 
cases showing negative PDGFB and positive CISH, 
PCGF3, and ANXA5 responses. This confirms that the 
efficacy of DCS therapy can be predicted using immuno-
histochemistry of biopsy samples. These data suggest 
that the patients judged as early responders should re-
ceive DCS therapy as the first-line treatment. In contrast, 
nonresponders should receive other forms of therapy, 
such as irinotecan-based or paclitaxel-based regimens. 
Thus, our results may contribute to the development of 
personalized medicine for unresectable metastatic gas-
tric cancer.
 There may, however, be some heterogeneity in the re-
sults of microarray, qPCR, and immunohistochemical 
staining. This heterogeneity was induced by the differ-
ence between the superficial and the deep portion of the 
tumor, and the result of the microarray may not demon-
strate the true properties of the tumor. Considering the 
molecular heterogeneity of gastric cancer, further analy-
sis of expression patterns and investigation using a scor-
ing system for expression grade is required to validate our 
results. It is also necessary to elucidate how these mole-
cules affect the anticancer drugs docetaxel, cisplatin, and 
S-1 independently. Moreover, the relationship between
the expression patterns of the 4 genes should be evaluated 
in a large-scale study of gastric cancer patients.
 In conclusion, we identified a group of genes in human 
tissue samples that are predictive of the therapeutic effi-
cacy of anticancer drugs for the treatment of unresectable 
AGC. These genes may serve as efficient biomarkers for 
personalized cancer-targeted therapy. Further investiga-
tions are needed to evaluate response rates, adverse ef-
fects, and survival period.
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